|Bid||149.47 x 900|
|Ask||149.49 x 800|
|Day's Range||147.45 - 150.36|
|52 Week Range||113.52 - 153.03|
|Beta (3Y Monthly)||1.10|
|PE Ratio (TTM)||14.32|
|Earnings Date||Feb 24, 2020 - Feb 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||174.56|
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 750 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]
Axsome (AXSM) announces data from a phase II study evaluating AXS-12 in narcolepsy patients, demonstrating statistically significant reduction in weekly cataplexy attacks.
Shares of IBD 50 stock Jazz Pharmaceuticals dipped Tuesday after Axsome Therapeutics unveiled promising Phase 2 test results for a rival narcolepsy treatment, known by the test name AXS-12.
Jazz Pharmaceuticals was upgraded to a 'Buy' recommendation by TheStreet.com's quantitative service today. Let's check out the price charts and technical indicators to see if they are in agreement.
Zacks.com featured highlights include: Jazz Pharmaceuticals, Mr. Cooper Group, Sonic Automotive, Hibbett Sports and Jones Lang LaSalle
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bruce Cozadd became the CEO of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in 2009. First, this article will compare CEO...
Jazz Pharmaceuticals, Canon, Advanced Energy Industries, Inphi and Skyworks Solutions highlighted as Zacks Bull and Bear of the Day